PTC Therapeutics, Inc. P/B ratio

P/B ratio of PTCT for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/B ratio growth rates and interactive chart. Measures the relationship between price and book value per share. Book value is the equity or owner's capital that is invested in a business. If a stock has a price of $10 and a book value per share of $10, the ratio is 1. Stock selling below a P/B of 1 can be a bargain, as the market price has declined below the net asset value of the business. It is more applicable to financial companies like banks and insurers, as their assets and liabilities are valued at market and the book value thus more accuraterly represents reality.

Highlights and Quick Summary

Current P/B ratio of PTC Therapeutics, Inc. is 8.72 (as of December 30, 2020)
  • P/B ratio for the quarter ending September 29, 2021 was 25.01 (a 65.56% increase compared to previous quarter)
  • Year-over-year quarterly P/B ratio increased by 186.79%
  • Annual P/B ratio for 2020 was 8.72 (a 83.36% increase from previous year)
  • Annual P/B ratio for 2019 was 4.76 (a 4.37% increase from previous year)
  • Annual P/B ratio for 2018 was 4.56 (a 4.22% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/B ratio of PTC Therapeutics, Inc.

Most recent P/B ratioof PTCT including historical data for past 10 years.

Interactive Chart of P/B ratio of PTC Therapeutics, Inc.

PTC Therapeutics, Inc. P/B ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 25.01 15.11 11.34
2020 8.72 6.19 5.77 5.26 8.72
2019 4.76 2.88 5.17 4.14 4.76
2018 4.56 5.79 5.85 7.19 4.56
2017 4.37 5.91 4.28 3.35 4.37
2016 3.2 3.41 1.44 1.11 3.2
2015 4.82 3.36 6.51 7.36 4.82
2014 5.48 6.42 3.43 2.62 5.48
2013 1.59 3.38 0.26 0.0 1.59
2012 0.0 0.0 0.0 0.0 0.0
2011 0.0

Business Profile of PTC Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.